Cambridge biotechs head for the (cheaper) 'burbs

Shire Human Genetic Therapies and a string of smaller drug developers have decided to pull up stakes from Cambridge and head for the suburbs. The report says the exodus is being triggered by a desire to find less expensive digs. The city has contributed to creating one of the biggest biotech clusters in the world, but developers have been balking at the high rents they face in town. For growing companies, the desire to get everyone under one roof can be a particular challenge.

- read the article in the Boston Globe

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.